<DOC>
	<DOC>NCT02701374</DOC>
	<brief_summary>In Post-Herpetic Neuralgia(PHN) patients: - To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study - To measure the plasma concentration of TRK-700 and its metabolites</brief_summary>
	<brief_title>Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<criteria>Patients with pain persisting for at least 3 months after the onset of herpes zoster Patients whose average pain score on the Numerical Rating Scale (NRS) over the past 24 hours at preliminary enrollment is at least 4 Patients with another skin disease that may affect the evaluation of the pain at the site of PHN Patients with pain other than PHN that may affect the evaluation of pain Patients with pain that is suspected to be mainly psychogenic Patients who have received neurolytic or neurosurgical therapy for PHN</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>TRK-700</keyword>
	<keyword>Post-Herpetic Neuralgia</keyword>
</DOC>